Symposium 2











Attenzione: apre in una nuova finestra.

2 Sunday, September 2, 10:15 am - 12:00 pm
Immuno-histology in GERD and Barrett's esophagus
Chairs:
M. Vieth (Bayreuth) – R. Fiocca (Genoa)
Discussant: N.S. Buttar (Rochester, MN)
Secretary: H. Neumann (Erlangen)

  • How does the stroma in BE differ from that of the normal esophagus? R.C. Fitzgerald (Cambridge)
  • How are the epithelial-stromal interactions and signaling pathways altered in association with fibro-muscular anomaly? R.H. Riddell (Toronto)
  • What is the role of tumor suppressor genes, including p16, p14 and p53 in BE? R. Fiocca (Genoa)
  • What is the role of proto-oncogenes in BE, including EGF, EGFR, HER2-neu? R.D. Odze (Boston)
  • How do immuno-histochemical markers differ comparing intestinal/tubular type adenocarcinomas in BE with carcinomas of fundic or signet-cell types? K. Takubo (Tokyo)
  • Does immuno-histochemistry have a role in grading of neoplasia in BE? As a way to define risk of progression to adenoca? M. Upton (Seattle)
  • Is there a combination of molecular tests and/or immuno-histochemistry that can improve management compared with H&E stained biopsies and surveillance? H.D. Appelman (Ann Arbor)
  • What is the role of CDX1 and CDX2 in squamous and cardiac mucosa? A. Bellizzi (Iowa City)
  • What is the role of desmosomal cadherins and lektins in squamous and cardiac mucosa? H. Neumann (Erlangen)